Sawant et al. found that the positive rate of C-MYC was 73.1% in FIGO stage III-IV and 51.0% in FIGO stage I-II, and its expression level was closely related to the differentiation degree and clinical stage of ovarian cancer cases. The gene discussed is MYC; the disease is ovarian carcinoma.